Generic Biosimilar Medicines Association

Making Medicines Affordable

Home
About GBMA
- Contact us
- GBMA Members
- Guiding principles
- Code of Practice
  - Code Complaint Committee
  - Historical Event Reporting
  - Annual Review
    - 2011
    - 2012
    - 2013
    - 2014
    - 2015
    - 2016
    - 2017
    - 2018
    - 2019
    - 2020
  - Lodging a complaint
- Media Enquiries
- Our Objectives
- Links
Advocacy
Generics
Biosimilars
Topics
News
- News 2021
- News 2020
- News 2019
- News 2018
- News 2017
- News 2016
- News 2015
- News 2014
GBMA Education
COVID-19 Virus
- COVID-19 Virus: The Facts

You are here: Home / Biosimilars / GBMA Position on Biosimilars / Key Figures on Biosimilars

Key Figures on Biosimilars

GBMA welcomes a new board member Medicine shortages, security of supply and affordability remain a key focus for 2021-22

May 19, 2021

19 May 2021 Canberra, ACT Protecting Australians from future medicine shortages and developing effective policies that … More...

Budget 2021-22: A Budget for the times – GBMA welcomes the boost in funding for health

May 12, 2021

11 May 2021 Canberra, ACT The Morrison Government tonight handed … More...

Government extends the GBMA Education biosimilar education campaign

May 7, 2021

7 May 2021 Canberra, ACT Australia’s patients, prescribers and pharmacists … More…

© 2021 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us